ArticleJCO oncology practice2023

Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective.

Minkyoung Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.